AU2021268204B2 - Novel compositions of matter and pharmaceutical compositions - Google Patents

Novel compositions of matter and pharmaceutical compositions

Info

Publication number
AU2021268204B2
AU2021268204B2 AU2021268204A AU2021268204A AU2021268204B2 AU 2021268204 B2 AU2021268204 B2 AU 2021268204B2 AU 2021268204 A AU2021268204 A AU 2021268204A AU 2021268204 A AU2021268204 A AU 2021268204A AU 2021268204 B2 AU2021268204 B2 AU 2021268204B2
Authority
AU
Australia
Prior art keywords
ethyl
indol
dimethylamino
indole
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021268204A
Other languages
English (en)
Other versions
AU2021268204A1 (en
Inventor
Jacqueline SALM
Christoper WITOWSKI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Psilera Inc
Original Assignee
Psilera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psilera Inc filed Critical Psilera Inc
Publication of AU2021268204A1 publication Critical patent/AU2021268204A1/en
Application granted granted Critical
Publication of AU2021268204B2 publication Critical patent/AU2021268204B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2021268204A 2020-05-08 2021-05-07 Novel compositions of matter and pharmaceutical compositions Active AU2021268204B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063021866P 2020-05-08 2020-05-08
US63/021,866 2020-05-08
US202063106516P 2020-10-28 2020-10-28
US63/106,516 2020-10-28
US202163134805P 2021-01-07 2021-01-07
US63/134,805 2021-01-07
PCT/US2021/031215 WO2021226416A1 (en) 2020-05-08 2021-05-07 Novel compositions of matter and pharmaceutical compositions

Publications (2)

Publication Number Publication Date
AU2021268204A1 AU2021268204A1 (en) 2022-12-08
AU2021268204B2 true AU2021268204B2 (en) 2026-07-16

Family

ID=78411868

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021268204A Active AU2021268204B2 (en) 2020-05-08 2021-05-07 Novel compositions of matter and pharmaceutical compositions

Country Status (7)

Country Link
US (9) US11759452B2 (cg-RX-API-DMAC7.html)
EP (1) EP4146198A4 (cg-RX-API-DMAC7.html)
JP (3) JP7655943B2 (cg-RX-API-DMAC7.html)
AU (1) AU2021268204B2 (cg-RX-API-DMAC7.html)
CA (1) CA3182156A1 (cg-RX-API-DMAC7.html)
IL (1) IL297861A (cg-RX-API-DMAC7.html)
WO (1) WO2021226416A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022550463A (ja) 2019-10-01 2022-12-01 エンピリアン ニューロサイエンス, インコーポレイテッド トリプタミン発現を調整する真菌の遺伝子操作
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc Novel compositions of matter and pharmaceutical compositions
WO2022120181A1 (en) * 2020-12-03 2022-06-09 Mydecine Innovations Group Inc. Novel psilocin analog compositions and methods of synthesizing the same
MX2023009491A (es) * 2021-02-12 2023-10-13 Enveric Biosciences Canada Inc Derivados de psilocibina de múltiples sustituyentes y métodos de uso.
CA3216889A1 (en) 2021-04-26 2022-11-03 Glenn Short Novel n,n-dimethyltryptamine compositions and methods
US20230136824A1 (en) 2021-04-26 2023-05-04 ATAI Life Sciences AG N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof
KR20240013170A (ko) 2021-05-25 2024-01-30 아타이 테라퓨틱스, 인크. 신규 n,n-디메틸트립타민 염 및 결정질 염 형태
IL309210A (en) 2021-06-09 2024-02-01 Atai Therapeutics Inc Parent drugs and conjugates of dimethyltryptamine
KR20240065084A (ko) * 2021-08-20 2024-05-14 테란 바이오사이언시스 인코포레이티드 사일로신의 전구약물 및 유도체 및 그의 용도
EP4423062A4 (en) * 2021-10-29 2025-08-27 Psilera Inc MODIFIED INDOLE COMPOUNDS
WO2023077245A1 (en) * 2021-11-08 2023-05-11 Nova Mentis Life Science Corp. Diagnosing, monitoring and treating neurological disease with psychoactive tryptamine derivatives and mrna measurements
CA3238440A1 (en) 2021-12-30 2023-07-06 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
WO2023130075A2 (en) 2021-12-31 2023-07-06 Empyrean Neuroscience, Inc. Genetically modified organisms for producing psychotropic alkaloids
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
US12065404B2 (en) 2022-03-18 2024-08-20 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using
AU2023235712A1 (en) * 2022-03-18 2024-11-07 Enveric Biosciences Canada Inc. C4-substituted tryptamine derivatives and methods of using
JP2025510368A (ja) * 2022-03-27 2025-04-14 ジーエイチ・リサーチ・アイルランド・リミテッド 不安の処置
AU2023254841B2 (en) * 2022-04-13 2025-10-23 Caamtech, Inc. Tryptamine derivatives
AU2023361184A1 (en) 2022-10-13 2025-04-24 Cybin Uk Ltd Method of administration of a parenteral formulation comprising a psychedelic agent
EP4608395A2 (en) * 2022-10-26 2025-09-03 ATAI Therapeutics, Inc. N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof
WO2024108195A1 (en) 2022-11-17 2024-05-23 Remedi, Inc. Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use
AU2024212866A1 (en) 2023-01-23 2025-08-07 Cybin Uk Ltd Treatment of psychiatric or neurological disorders by parenteral administration of a single, effective parenteral dose of a short-acting psychedelic agent
US12396981B2 (en) 2023-03-09 2025-08-26 William Shulman Methods of using DMT
US20240325351A1 (en) 2023-03-31 2024-10-03 Cybin UK Ltd. Method of administration
JP2026518190A (ja) * 2023-05-24 2026-06-04 サイレラ インコーポレイテッド トリプタミン誘導体を含む製剤およびそれらの使用
JP2026524104A (ja) 2023-06-28 2026-07-17 サイロ プロプリエタリー リミテッド 化合物
EP4735441A1 (en) 2023-06-28 2026-05-06 Psylo Pty Ltd Pyrrolopyridine compounds for the treatment of mental illnesses
CA3256375A1 (en) * 2023-09-29 2026-03-01 Babak Ghalili Drug addiction treatment and menthol transdermal delivery systems and methods
WO2025170990A1 (en) * 2024-02-06 2025-08-14 Atai Therapeutics, Inc. Controlled transmucosal release of dmt in combination with a monoamine oxidase inhibitor
WO2025250900A1 (en) * 2024-05-30 2025-12-04 Caamtech, Inc. 4-hydroxy-n,n-diisopropyltryptaminium hydroglutarate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180021326A1 (en) * 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
US20180221396A1 (en) * 2017-02-09 2018-08-09 CaaMTech, LLC Compositions and methods comprising a psilocybin derivative

Family Cites Families (290)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US359439A (en) 1887-03-15 Thomas f
US378130A (en) 1888-02-21 Apparatus foe inserting and fixing the bristles of beushes
US2774763A (en) 1956-12-18 Preparation of amides of lysergic age
US860913A (en) 1906-09-13 1907-07-23 Max Haeberlein Oil-brake for speed-governors.
US2997470A (en) 1956-03-05 1961-08-22 Lilly Co Eli Lysergic acid amides
GB912715A (en) 1958-02-21 1962-12-12 Sandoz Ltd 4-hydroxytryptamines
US3078214A (en) 1958-09-12 1963-02-19 Sandoz Ag Treatment of mental disturbances with esters of indoles
GB981192A (en) 1960-03-30 1965-01-20 Westminster Bank Ltd Improvements in or relating to 4 hydroxytryptamine esters
US3224945A (en) 1963-05-06 1965-12-21 College Of Pharmacy Process for the production of ergot alkaloids
GB1164828A (en) 1965-10-23 1969-09-24 Robins Co Inc A H 3-(2-Substituted Ethyl)Indoles and their Manufacture and Use
US3781300A (en) * 1969-06-09 1973-12-25 American Home Prod Method of producing 2-halo-3-substituted indoles
US3594391A (en) 1969-06-09 1971-07-20 American Home Prod 2-halo-3-substituted indoles
BE792515A (fr) 1971-12-10 1973-06-08 Sandoz Sa Nouveaux derives de l'acide lysergique, leur preparation et leur application comme medicaments
CH578565A5 (en) 1972-12-07 1976-08-13 Sandoz Ag N-(2-amino-5-pyridyl) lysergic acid amides - with saluretic and serotonin antagonist activity
HU172649B (hu) 1975-04-24 1978-11-28 Gyogyszerkutato Intezet Sposob poluchenija novykh biologicheski aktivnykh lizergamidov
DE2656344A1 (de) 1975-12-23 1977-07-07 Sandoz Ag Ergolinderivate, ihre verwendung und herstellung
IT1064473B (it) 1976-11-24 1985-02-18 Simes Sulfamoil derivati dell'8-beta-amminometilergolina
DE2802023A1 (de) 1977-01-28 1978-08-03 Sandoz Ag Neue ergotderivate, ihre herstellung und verwendung
GB1584464A (en) 1977-04-19 1981-02-11 Farmaceutici Italia Ergot alkaloids
AU526764B2 (en) 1978-09-08 1983-01-27 Farmitalia Carlo Erba S.P.A. Ergoline derivatives
ZA795239B (en) 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
EP0026899A1 (de) 1979-10-09 1981-04-15 Sandoz Ag Peptidergotalkaloide, Verfahren zu deren Herstellung, diese enthaltende pharmakologische Zusammensetzungen und ihre Anwendung bei der therapeutischen Behandlung
GB8318790D0 (en) 1983-07-12 1983-08-10 Erba Farmitalia Anorexigenic ergot derivatives
US5340838A (en) 1990-05-04 1994-08-23 Eli Lilly And Company Method of inhibiting gastric acid secretion with 2-phenylcyclopropylamines
CA2102303A1 (en) 1991-06-19 1992-12-20 Roy Allen Johnson Dialkyl (dialkoxyphosphinyl) methyl phosphates as anti-inflammatory agents
JP3361836B2 (ja) 1991-07-04 2003-01-07 三共株式会社 アミノ酸誘導体
GB9226532D0 (en) 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
WO1995006638A1 (en) 1993-09-01 1995-03-09 Allelix Biopharmaceuticals Inc. Tryptamine analogs with 5-ht1d selectivity
GB9402029D0 (en) 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
JPH09510216A (ja) 1994-03-11 1997-10-14 イーライ・リリー・アンド・カンパニー 5−ht▲下2b▼受容体に関連する病態を治療するための方法
US6025374A (en) 1994-12-06 2000-02-15 Merck Sharp & Dohme, Ltd. Azetidine, pyrrolidine and piperidine derivatives as 5HT1 receptor agonists
WO1997043281A1 (en) 1996-05-16 1997-11-20 Allelix Biopharmaceuticals Inc. Thiophene- and furan-tryptamine derivatives
EP0821957A3 (en) * 1996-08-01 1998-04-22 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating substance abuse
US6500456B1 (en) 1997-10-03 2002-12-31 Warner-Lambert Company Compressed nitroglycerin tablet and its method of manufacture
DE19803376C1 (de) 1998-01-29 1999-10-14 Markus Storz Inhalator zur Erzeugung von aroma- und/oder wirkstoffhaltigen Dämpfen aus Pflanzenmaterial und/oder Flüssigkeiten
US6436950B1 (en) 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
NZ510988A (en) 1998-10-07 2005-01-28 Ortho Mcneil Pharm Inc N-aralkylaminotetralins useful as ligands for the neuropeptide Y5 receptor
US6376531B1 (en) 1998-11-13 2002-04-23 Rupert Charles Bell Method of treatment using deuterium compounds
US6403808B1 (en) 1999-12-10 2002-06-11 Virginia Commonwealth University Selective 5-HT6 receptor ligands
US6488648B1 (en) 1999-01-14 2002-12-03 Teijin Limited Device for feeding a powder in a predetermined amount and method thereof
NZ514442A (en) 1999-03-03 2003-08-29 Optinose As Nasal delivery device
GB0114272D0 (en) 2001-06-12 2001-08-01 Optinose As Nasal delivery device
GB0121568D0 (en) 2001-09-06 2001-10-24 Optinose As Nasal delivery device
HUP0202143A3 (en) 1999-07-28 2003-12-29 Ortho Mcneil Pharm Inc Amine and amide derivatives as ligands for the neuropeptide y y5 receptor pharmaceutical compositions containing them and their use
WO2001015677A2 (en) 1999-08-31 2001-03-08 Alcon Laboratories, Inc. Use of 5-ht1b/1d agonists to treat otic pain
DE10007948A1 (de) 2000-02-22 2001-09-06 Wella Ag Mittel zur Färbung von Fasern
US20020052370A1 (en) 2000-07-06 2002-05-02 Barber Christopher Gordon Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
ES2172415B2 (es) 2000-07-28 2003-11-16 Univ Madrid Complutense Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
GB0019715D0 (en) 2000-08-10 2000-09-27 Pa Consulting Services Device for delivering physiologically active agent in powdered form
WO2002038142A2 (en) 2000-11-08 2002-05-16 Massachusetts Institute Of Technology Serotonergic compositions and methods for treatment of mild cognitive impairment
KR100523257B1 (ko) 2000-12-29 2005-10-24 삼성전자주식회사 포지티브형 감광성 폴리이미드 전구체 및 이를 포함하는조성물
ZA200306564B (en) 2001-02-26 2004-10-15 Optinose As Nasal devices.
ES2566056T3 (es) 2001-03-29 2016-04-08 Eli Lilly And Company N-(2-ariletil)bencilaminas como antagonistas del receptor 5-HT6
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
ITRM20010356A1 (it) 2001-06-21 2002-12-23 Sigma Tau Ind Farmaceuti "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
US20050245594A1 (en) 2001-06-29 2005-11-03 Sutter Diane E Dermal delivery of anti-pain agents and methods useful thereof
GB0117827D0 (en) 2001-07-21 2001-09-12 Igt Uk Ltd Entertainment machines
AU2002340083A1 (en) 2001-09-28 2003-04-07 Kurve Technology, Inc Nasal nebulizer
ITMI20012174A1 (it) 2001-10-18 2003-04-18 Univ Parma Polvere per somministrazione nasale di farmaci
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
GB0207422D0 (en) 2002-03-28 2002-05-08 Optinose As Nasal devices
GB0207817D0 (en) 2002-04-04 2002-05-15 Optinose As Nasal devices
GB0209494D0 (en) 2002-04-25 2002-06-05 Optinose As Nasal devices
ES2297216T3 (es) 2002-06-21 2008-05-01 Suven Life Sciences Limited Indoles tetraciclicos arilsulfonil que tienen afinidad con el receptor de la serotonina.
WO2004030075A1 (ja) 2002-09-26 2004-04-08 Renesas Technology Corp. 半導体装置の製造方法
CN1685732B (zh) 2002-11-01 2010-10-13 松下电器产业株式会社 画像编码方法及装置、画像解码方法及装置
US20040127409A1 (en) 2002-11-07 2004-07-01 Milkhaus Laboratory, Inc. Method of treatment of psychological conditions by administration of nerve growth factor
WO2004085392A1 (en) 2003-03-25 2004-10-07 Faust Pharmaceuticals Melatonin derivatives and their use for treating neurological dysfunctions
US20040214832A1 (en) 2003-04-10 2004-10-28 Cuiman Cai Piperazine derivative renin inhibitors
CA2526478A1 (en) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same
US20050152858A1 (en) 2003-07-11 2005-07-14 Isp Investments Inc. Solubilizing agents for active or functional organic compounds
JP2005102086A (ja) 2003-09-26 2005-04-14 Renesas Technology Corp 半導体装置およびレベル変換回路
JP2005122773A (ja) 2003-10-14 2005-05-12 Matsushita Electric Ind Co Ltd 光ディスク装置および信号処理装置と光ディスク装置の再生制御方法
AU2005244770A1 (en) 2004-04-26 2005-12-01 Vanderbilt University Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity
DE102004036034B3 (de) 2004-07-24 2005-11-24 Robert Bosch Gmbh Verfahren zur Steuerung einer Brennkraftmaschine
WO2006099416A1 (en) 2005-03-11 2006-09-21 Nitromed, Inc. 2-methyl indole cyclooxygenase-2 selective inhibitors, compositions and methods of use
KR100860544B1 (ko) 2005-03-14 2008-09-26 윤석태 스플리트 롤러 베어링 케이지의 자기 체결장치
WO2006105615A1 (en) * 2005-04-08 2006-10-12 Ozpharma Pty Ltd Buccal delivery system
JP2008547157A (ja) 2005-06-01 2008-12-25 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 再充電できるリチウムイオン電池用のカソード
EP1962837A4 (en) 2005-12-20 2011-12-14 Teikoku Pharma Usa Inc METHODS OF PERCUTANEOUS DELIVERY OF INDOLIC SEROTONIN RECEPTOR AGONIST AND PERCUTANEOUS COMPOSITIONS FOR USE THEREIN
US7429575B2 (en) 2006-01-10 2008-09-30 Yu Ruey J N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use
CA2642685A1 (en) 2006-02-17 2007-08-30 Gilead Colorado, Inc. Antihypertensive therapy
HRP20120479T1 (hr) 2006-06-28 2012-07-31 Chelsea@Therapeutics@Inc Farmaceutski sastavi sa droksidopom
CN2920112Y (zh) 2006-07-03 2007-07-11 于乔治 带有热水杀菌系统的桶装水饮水机
DE502006008441D1 (de) 2006-08-01 2011-01-13 Stobi Gmbh & Co Kg Ventilballon für Inhalatoren
ATE453416T1 (de) 2006-08-23 2010-01-15 Blue Medical Devices B V Medizinischer stent mit einer kombination aus melatonin und paclitaxel
US7482273B1 (en) 2006-09-11 2009-01-27 United States Of America As Represented By The Secretary Of The Air Force Transmissive dynamic plasma steering method for radiant electromagnetic energy
EP2420235A1 (en) 2006-10-27 2012-02-22 Medivation Neurology, Inc. Methods and combination therapies for treating alzheimer's disease
US20080293695A1 (en) 2007-05-22 2008-11-27 David William Bristol Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance
US20080248511A1 (en) 2007-03-26 2008-10-09 Promega Corporation Methods to quench light from optical reactions
CA2686994A1 (en) 2007-05-11 2008-11-20 Mpex Pharmaceuticals, Inc. Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof
US8318813B2 (en) 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
EP2209380A4 (en) 2007-10-09 2011-09-14 Mark T Hamann METHOD OF USE OF COMPOSITIONS WITH ANTIDEPRESSIVE EFFICACY, MOOD EFFICACY AND OTHER NEUROLOGICAL EFFECTIVENESS AND COMPOSITIONS THEREOF
EP2083008A1 (en) 2007-12-07 2009-07-29 Axxonis Pharma AG Ergoline derivatives as selective radical scavengers for neurons
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
JP5620907B2 (ja) * 2008-06-19 2014-11-05 エルテーエスローマン テラピー−ジステーメ アーゲー カチオン性活性剤の経皮送達のための組成物
BRPI0919920A2 (pt) 2008-10-22 2016-02-16 Acucela Inc compostos para tratamento de doenças e desordens oftálmicas
US9433793B2 (en) 2008-11-03 2016-09-06 Pacesetter, Inc. System and method for accurately detecting cardiac events using multi-threshold processing
WO2010054202A2 (en) 2008-11-06 2010-05-14 Leon Rosenberg Package of pills useful for titration and method of titrating a patient
AU2010251930A1 (en) 2009-05-27 2011-11-24 Universite Libre De Bruxelles 3-alkyl-5-fluoroindole derivatives as myeloperoxidase inhibitors
WO2010151258A1 (en) 2009-06-24 2010-12-29 The Board Of Regents Of The University Of Oklahoma Methods of treating psychological conditions
US8912220B2 (en) 2009-08-10 2014-12-16 Galenea Pharmaceuticals Compounds and methods of use thereof
WO2011041870A1 (en) 2009-10-07 2011-04-14 Nitrogenix Inc. Non-steroidal anti-inflammatory drugs coadministered with nitric oxide amino acid ester compounds as prophylaxis in hypertensive patients
US20120108510A1 (en) 2010-05-20 2012-05-03 Emory University Methods of improving behavioral therapies
EP2418196A1 (en) 2010-07-29 2012-02-15 IMTM GmbH Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors
CN103249407B (zh) 2010-10-07 2017-05-17 鹰制药私人有限公司 用于治疗抑郁症和其他非感染性疾病的联合疗法
US20140221499A1 (en) 2011-06-16 2014-08-07 President And Fellows Of Harvard College Novel rodent control agents and uses thereof
US9073851B2 (en) 2011-10-28 2015-07-07 Board Of Regents, The University Of Texas System Compositions and methods for treating cancer
WO2013142770A1 (en) 2012-03-23 2013-09-26 Codexis, Inc. Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs
EP2830599B1 (en) 2012-03-29 2018-08-15 Therabiome, Llc Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
CA2876321A1 (en) 2012-06-22 2013-12-27 Map Pharmaceuticals, Inc. Novel cabergoline derivatives
JP2015521988A (ja) * 2012-07-06 2015-08-03 イガレット・リミテッド 制御放出用乱用防止性医薬組成物
CN102816103B (zh) 2012-08-20 2014-05-07 冉瑞琼 硫化天冬氨酸修饰的退黑素衍生物及其应用
US9580400B2 (en) 2013-02-26 2017-02-28 Northeastern University Cannabinergic nitrate esters and related analogs
EP2796139A1 (en) 2013-04-26 2014-10-29 AOP Orphan Pharmaceuticals AG Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
FR3007992B1 (fr) 2013-07-05 2018-01-26 Aptar France Sas Dispositif de distribution de produit fluide ou pulverulent.
US9549942B2 (en) 2013-07-15 2017-01-24 Research & Business Foundation Sungkyunkwan University Composition for preventing or treating degenerative brain diseases including compound downregulating expression of BACE1 proteins
TWI659017B (zh) 2013-11-24 2019-05-11 臺北醫學大學 吲哚基及吲哚啉基異羥肟酸於治療神經退化病症或認知缺乏之用途
JP6510539B2 (ja) 2014-01-09 2019-05-08 ザ ジェイ. デヴィッド グラッドストーン インスティテューツ, ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ. デヴィッド グラッドストーン 置換ベンゾオキサジン及び関連化合物
EP3110419A4 (en) 2014-02-25 2017-07-26 Achillion Pharmaceuticals, Inc. Alkyne compounds for treatment of complement mediated disorders
CN103816150A (zh) 2014-03-14 2014-05-28 兰州理工大学 山蚂蝗生物碱单体成分的用途
GB201409516D0 (en) 2014-05-29 2014-07-16 Randox Lab Ltd Immunoassay for compounds of the NBOMe family
JP6856532B2 (ja) 2015-01-20 2021-04-07 エックスオーシー ファーマシューティカルズ インコーポレイテッドXoc Pharmaceuticals, Inc エルゴリン化合物およびその使用
EP3268086A4 (en) 2015-03-10 2018-11-07 Eleusis Benefit Corporation, PBC Lsd for the treatment of alzheimer's disease
US20180147142A1 (en) 2015-05-19 2018-05-31 Joseph Robert Knight Method for isolation of alkaloids and amino acids, and compositions containing isolated alkaloids and amino acids
US20220079881A1 (en) 2016-03-03 2022-03-17 Ctt Pharma Inc. Orally Administrable Composition
KR20220071293A (ko) 2016-04-01 2022-05-31 리커리엄 아이피 홀딩스, 엘엘씨 에스트로겐 수용체 조절제
CN206543131U (zh) 2016-07-08 2017-10-10 深圳西诺咖啡机制造有限公司 一种可酿造多种咖啡胶囊的酿造装置
US20210069170A1 (en) 2016-07-23 2021-03-11 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth
EP3519816A4 (en) 2016-09-29 2020-05-06 The Regents of the University of California CONNECTIONS FOR INCREASING NEURONAL PLASTICITY
WO2018081456A1 (en) * 2016-10-26 2018-05-03 University Of Florida Research Foundation, Incorporated Highly active self-sufficient nitration biocatalysts
WO2018094005A1 (en) 2016-11-16 2018-05-24 The General Hospital Corporation Myeloperoxidase imaging agents
WO2018094106A2 (en) 2016-11-16 2018-05-24 University Of South Florida ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES
WO2018106907A1 (en) 2016-12-08 2018-06-14 Novatarg, Inc. Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therary
US11974984B2 (en) 2017-02-09 2024-05-07 Caamtech, Inc. Compositions and methods comprising a combination of serotonergic drugs
KR101934048B1 (ko) 2017-03-09 2019-03-26 고려대학교 산학협력단 플라빈-의존형 할로게나아제 및 이를 이용한 할로겐화 인돌 화합물의 제조방법
US20200147038A1 (en) 2017-04-20 2020-05-14 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
EP3655406A1 (en) 2017-07-18 2020-05-27 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyridine-derivatives
JP7403050B2 (ja) * 2017-08-28 2023-12-22 ユニバーシティ オブ メリーランド ボルチモア 気分障害のための新規ガンマアミノ酪酸型受容体モジュレーター
GB201715919D0 (en) 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
GB2588505B (en) 2017-10-09 2022-08-03 Compass Pathfinder Ltd Preparation of psilocybin
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US11723894B2 (en) 2017-10-26 2023-08-15 Terran Biosciences, Inc. Combination product for the treatment of neurological and/or psychiatric disorders
WO2019099402A1 (en) 2017-11-14 2019-05-23 Rutgers, The State University Of New Jersey Therapeutic compounds and methods to treat infection
JP2021514682A (ja) 2018-03-08 2021-06-17 ニュー アトラス バイオテクノロジーズ エルエルシー トリプタミンの生産方法
CN118121577A (zh) 2018-05-04 2024-06-04 感知神经科学公司 治疗物质滥用的方法
US10813116B2 (en) 2018-05-11 2020-10-20 Apple Inc. Support of advanced user equipment (UE) minimum processing times in new radio (NR) systems
EP3813810A4 (en) 2018-06-21 2022-03-30 Robert John Petcavich METHODS OF INDUCING DENDRITICAL AND SYNAPTIC GENESIS IN CHRONIC NEURODEGENERATIVE DISEASES
WO2020023084A1 (en) 2018-07-26 2020-01-30 Applied Biology, Inc. Taar receptor agonists for the treatment of alopecia
EP3841085B1 (en) 2018-08-22 2026-05-06 University Of Technology Sydney Nbome test
CN112912016A (zh) 2018-11-07 2021-06-04 巴克斯特国际公司 双止回阀单手涂敷器
US11045454B2 (en) 2018-12-06 2021-06-29 Palo Alto Investors LP Methods of treating food allergy conditions
WO2020124073A1 (en) 2018-12-14 2020-06-18 Pear Therapeutics, Inc. A digital therapeutic component to optimize induction of buprenorphine-containing products
MX2021009037A (es) 2019-01-30 2021-10-13 Diamond Therapeutics Inc Composiciones y metodos para el manejo de trastornos.
HUE066828T2 (hu) 2019-02-22 2024-09-28 Gh Res Ireland Limited 5-Metoxi-N,N-Dimetiltriptamin (5-Meo-Dmt) súlyos depressziós rendellenesség kezelésére
DK3927338T3 (da) 2019-02-22 2025-01-06 Gh Res Ireland Limited Sammensætninger omfattende 5-methoxy-n,n-dimethyltryptamin (5-meo-dmt) til anvendelse i behandling af mentale lidelser
WO2020176597A1 (en) 2019-02-27 2020-09-03 The Regents Of The University Of California N-substituted indoles and other heterocycles for treating brain disorders
US12616706B2 (en) 2019-03-07 2026-05-05 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
KR20220008824A (ko) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
WO2021003467A1 (en) 2019-07-04 2021-01-07 Sw Holdings, Inc. Metered dosing compositions and methods of use of psychedelic compounds
FR3098407B1 (fr) 2019-07-10 2024-12-13 Aptar France Sas Dispositif de distribution nasale de poudre
US20210015738A1 (en) 2019-07-17 2021-01-21 Concept Matrix Solutions Oral dissolvable film containing psychedelic compound
GB201911024D0 (en) 2019-08-01 2019-09-18 Beckley Found Compounds for use in a method of treating or preventing neurological and/or psychiatric disorders
WO2021030571A1 (en) 2019-08-13 2021-02-18 University Of Maryland, Baltimore Methods of treating psychological and brain disorders
WO2021041407A1 (en) 2019-08-25 2021-03-04 Caamtech Llc Alkyl quarternary ammonium tryptamines and their therapeutic uses
US20230295106A1 (en) 2019-10-14 2023-09-21 The Regents Of The University Of California Ergoline-like compounds for promoting neural plasticity
HRP20220797T1 (hr) 2019-11-07 2022-10-14 Small Pharma Ltd Spojevi
US11660305B2 (en) 2019-11-19 2023-05-30 Turtle Bear Holdings, Llc Tryptamine compositions for enhancing neurite outgrowth
KR20220110759A (ko) 2019-12-06 2022-08-09 나넥사 에이비 신규 조성물
MX2022009527A (es) 2020-02-04 2022-11-16 Mindset Pharma Inc Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc.
US20210236523A1 (en) 2020-02-05 2021-08-05 Yale University Psychedelic treatment for headache disorders
LT4084791T (lt) 2020-02-18 2025-02-25 Gilgamesh Pharmaceuticals, Inc. Specifiniai triptaminai, skirti nuotaikos sutrikimams gydyti
EP3868364A1 (en) 2020-02-24 2021-08-25 GH Research Limited Aerosol comprising 5-methoxy-n,n-dimethyltryptamine
GB202003059D0 (en) 2020-03-03 2020-04-15 Beckley Found Compounds for use in a method of treating, preventing and/or reducing the symptoms of pain
WO2021179091A1 (en) 2020-03-12 2021-09-16 Bright Minds Biosciences Inc. 3-(2-(aminoethyl)-indol-4-ol derivatives, methods of preparation thereof, and the use as 5-ht2 receptor modulators
AU2021237640B2 (en) 2020-03-19 2024-01-04 Caamtech, Inc. Crystalline psilacetin derivatives
US11358934B2 (en) 2020-03-23 2022-06-14 Caamtech, Inc. Crystalline forms of psilacetin
US11332441B2 (en) 2020-03-23 2022-05-17 Caamtech, Inc. Crystalline N-methyl tryptamine derivatives
CA3173048A1 (en) 2020-04-16 2021-10-21 Fotios M. Plakogiannis Transdermal micro-dosing delivery of psychedelics derivatives
US20210322743A1 (en) 2020-04-20 2021-10-21 Indian Institute Of Technology Bombay Microneedle array patch for drug delivery and production method thereof
US20210322306A1 (en) 2020-04-21 2021-10-21 Cure Pharmaceutical Holding Corp. Oral dissolvable film with high load of polymeric binder
EP4142693A1 (en) 2020-05-01 2023-03-08 Emergex USA Corporation Transdermal drug delivery devices having psilocybin, lysergic acid diethylamide or 3,4-methylenedioxymethamphetamine coated microprotrusions
WO2021226041A1 (en) 2020-05-04 2021-11-11 Caamtech, Inc. Crystalline dimethyl tryptamine analogues
AU2021267101B2 (en) 2020-05-05 2024-03-28 Universitätsspital Basel MDMA treatment to enhance acute emotional effects profile of LSD, psilocybin or other psychedelics
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc Novel compositions of matter and pharmaceutical compositions
IL312785B2 (en) 2020-05-19 2026-06-01 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
WO2021116503A2 (en) 2020-06-02 2021-06-17 Small Pharma Ltd Deuterated compounds
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
BR112022025306A2 (pt) 2020-06-12 2023-02-28 Beckley Psytech Ltd Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina
GB202008961D0 (en) 2020-06-12 2020-07-29 Beckley Psytech Ltd Pharmaceutical composition
CA3173030C (en) 2020-06-17 2024-05-14 Psilo Scientific Ltd. Predominantly phosphorylated psychoactive alkaloid extraction using alkali
CA3103707C (en) 2020-12-18 2023-09-26 Ryan Moss Standardized psychoactive alkaloid extract composition
EP4167992A1 (en) 2020-06-22 2023-04-26 University of Zürich Compositions and kits of parts comprising n,n-dimethyltryptamine and harmine and their use in therapy
DK4172145T3 (da) 2020-06-30 2026-07-20 Reunion Neuroscience Inc Tryptamin-prodrugs som serotonin-receptor-aktivatorer til behandling af f.eks. depression
WO2022008627A2 (en) 2020-07-07 2022-01-13 Compass Pathfinder Limited Improved method for the production of lysergic acid diethylamide (lsd) and novel derivatives thereof
AU2021311493A1 (en) 2020-07-24 2023-03-16 Mindset Pharma Inc. Scalable synthetic route for psilocin and psilocybin
AU2021328726A1 (en) 2020-08-21 2023-03-02 Compass Pathfinder Limited Novel psilocin derivatives having prodrug properties
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
EP4208457A1 (en) 2020-09-04 2023-07-12 Gilgamesh Pharmaceuticals, Inc. Azetidinyl tryptamines and methods of treating psychiatric disorders
CA3192617A1 (en) 2020-09-20 2022-03-24 Matthew BAGGOTT Advantageous tryptamine compositions for mental disorders or enhancement
WO2022082058A1 (en) 2020-10-16 2022-04-21 Eleusis Therapeutics Us, Inc. Method of treatment by tryptamine alkaloids
US20230405026A1 (en) 2020-11-06 2023-12-21 Mynd Life Sciences Inc. A Method of Treating Depression by Immune Modulation
EP4247340A4 (en) 2020-11-18 2024-10-02 Bexson Biomedical, Inc. COMPLEXING SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS
WO2022104475A1 (en) 2020-11-19 2022-05-27 Magicmed Industries Inc. Nitrilated psilocybin derivatives and methods of using
EP4031529B1 (en) 2020-12-01 2023-09-27 Small Pharma Ltd Deuterated or partially deuterated n,n-dimethyltryptamine compounds
WO2022123232A1 (en) 2020-12-07 2022-06-16 Beckley Psytech Limited Pharmaceutical composition comprising psilocybin or its polymorphs
FR3117046B1 (fr) 2020-12-09 2023-02-10 Aptar France Sas Dispositif de distribution de doses de poudre
CA3201913A1 (en) 2020-12-09 2022-06-16 Andrew R. Chadeayne Dialkyl trytamines and their therapeutic uses
JP2024500397A (ja) 2020-12-18 2024-01-09 コンパス パスファインダー リミテッド 治療用途のための修飾インドールアルカロイド
EP4274831A4 (en) 2021-01-11 2024-05-01 Caamtech, Inc. Quaternary tryptamines and their therapeutic uses
EP4126857A1 (en) 2021-01-15 2023-02-08 Beckley Psytech Limited Ergoline analogues
EP4277894A1 (en) 2021-01-15 2023-11-22 Beckley Psytech Limited Tryptamine analogues
WO2022160056A1 (en) 2021-01-29 2022-08-04 Algernon Pharmaceuticals Inc. Dmt salts and their use to treat brain injury
MX2023009491A (es) 2021-02-12 2023-10-13 Enveric Biosciences Canada Inc Derivados de psilocibina de múltiples sustituyentes y métodos de uso.
US20240189331A1 (en) 2021-02-12 2024-06-13 Intelgenx Corp. Novel tryptamine oral film formulation
FR3119772B1 (fr) 2021-02-15 2024-06-14 Aptar France Sas Tête de distribution pour dispositif de distribution nasale d’un produit fluide ou pulvérulent
US20220273628A1 (en) 2021-02-19 2022-09-01 Universitätsspital Basel Effects of lysergic acid diethylamide (lsd) and of lsd analogs to assist psychotherapy for generalized anxiety disorder or other anxiety not related to life-threatening illness
WO2022189662A1 (en) 2021-03-12 2022-09-15 Alvarius Pharmaceuticals Ltd. Compositions and methods for treating addictions comprising 5-meo-dmt
CA3212065A1 (en) 2021-03-15 2022-09-22 James Gilligan Improved methods for the use of psychedelics
AU2022239825C1 (en) 2021-03-18 2026-08-13 Cybin Irl Limited Psilocybin analogs, salts, compositions, and methods of use
CN117177959A (zh) 2021-03-18 2023-12-05 赛本爱尔兰有限公司 裸头草碱类似物、盐、组合物和使用方法
FR3121047B1 (fr) 2021-03-29 2023-07-14 Aptar France Sas Dispositif de distribution nasale de poudre
MX2023011326A (es) 2021-03-30 2023-10-03 Compass Pathfinder Ltd Composiciones de psilocibina, metodos para prepararlas y metodos de uso de estas.
CA3216889A1 (en) 2021-04-26 2022-11-03 Glenn Short Novel n,n-dimethyltryptamine compositions and methods
US20230136824A1 (en) 2021-04-26 2023-05-04 ATAI Life Sciences AG N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof
US20220362237A1 (en) 2021-05-03 2022-11-17 Mind Medicine, Inc. Psychedelics for treatment of pain
EP4333979A4 (en) 2021-05-03 2025-01-15 Mind Medicine, Inc. Method of titrating dose of psychedelics
WO2022235514A1 (en) 2021-05-04 2022-11-10 Mind Medicine, Inc. Liposome delivery of psychedelics
EP4792879A2 (en) 2021-05-17 2026-08-19 Cybin IRL Limited Formulations of psilocybin
CN113288883A (zh) 2021-05-24 2021-08-24 河南科技大学 一种长效缓解抑郁微针贴片及其制备方法
KR20240013170A (ko) 2021-05-25 2024-01-30 아타이 테라퓨틱스, 인크. 신규 n,n-디메틸트립타민 염 및 결정질 염 형태
WO2022246572A1 (en) 2021-05-26 2022-12-01 Mindset Pharma Inc. Hallucinogen-fatty acid combination
IL309210A (en) 2021-06-09 2024-02-01 Atai Therapeutics Inc Parent drugs and conjugates of dimethyltryptamine
US20230024991A1 (en) 2021-06-23 2023-01-26 ATAI Life Sciences AG Prodrugs of acyl carnitines
WO2023283386A2 (en) 2021-07-07 2023-01-12 Arcadia Medicine, Inc. Safer psychoactive compositions
IL310296A (en) 2021-07-22 2024-03-01 Gh Res Ireland Limited A method for the preparation of a tryptamine derivative
EP4137131A1 (en) 2021-08-17 2023-02-22 Centre National de la Recherche Scientifique (CNRS) Novel serotonin analogues and their uses for treating iron-associated disorders
WO2023028086A1 (en) 2021-08-23 2023-03-02 Gilgamesh Pharmaceuticals, Inc. Combinations of peripheral 5-ht2a receptor antagonists and central 5-ht2a receptor agonists
AU2022342266B2 (en) 2021-09-08 2026-03-26 Cybin Irl Limited Combination drug therapies
EP4159201A1 (en) 2021-09-30 2023-04-05 Biomind Labs Inc Encapsulated microparticles and nanoparticles of dimethyltriptamines
EP4408412A4 (en) 2021-09-30 2025-07-16 ATAI Life Sciences AG COMPOSITIONS AND METHODS FOR TREATING HEADACHES
US20230310374A1 (en) 2021-09-30 2023-10-05 ATAI Life Sciences AG Compositions and methods for treating headache or facial pain
EP4159192A1 (en) 2021-09-30 2023-04-05 Biomind Labs Inc Dimethyltriptamine-based nasal spray for the personalised treatment of neurological and psychiatric disorders
WO2023076135A1 (en) 2021-10-29 2023-05-04 Psilera Inc. N,n-dimethyltryptamine (dmt) crystalline products and methods of making the same
EP4423062A4 (en) 2021-10-29 2025-08-27 Psilera Inc MODIFIED INDOLE COMPOUNDS
AU2022413759A1 (en) 2021-12-13 2024-06-27 Beckley Psytech Limited Benzoate salt of 5-methoxy-n,n-dimethyltryptamine
US20260041667A1 (en) 2021-12-13 2026-02-12 Beckley Psytech Limited Prescription digital therapeutics
US20260035334A1 (en) 2021-12-13 2026-02-05 Beckley Psytech Limited Method of synthesis
US20250064782A1 (en) 2021-12-17 2025-02-27 Journey Colab Corp. Methods of Treating Substance Use Disorders Using 5-MeO-DMT
CA3244229A1 (en) 2021-12-24 2023-06-29 Psylo Pty Ltd COMPOUNDS
JP2025501141A (ja) 2021-12-24 2025-01-17 サイロ プロプリエタリー リミテッド 化合物
US11912680B2 (en) 2021-12-28 2024-02-27 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA
CA3238440A1 (en) 2021-12-30 2023-07-06 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
KR20250005182A (ko) 2022-03-27 2025-01-09 지에이치 리서치 아일랜드 리미티드 인지기능 장애 치료를 위한 5-메톡시-n,n-다이메틸트립타민
WO2023186834A1 (en) 2022-03-27 2023-10-05 GH Research Ireland Limited Crystalline hydrobromide salt of 5-meo-dmt
JP2025510368A (ja) 2022-03-27 2025-04-14 ジーエイチ・リサーチ・アイルランド・リミテッド 不安の処置
WO2024010537A1 (en) 2022-07-07 2024-01-11 Cemaks Endüstri̇yel Maki̇ne Sanayi̇ Anoni̇m Şi̇rketi̇ Packaging machine for packaging polymer based products
AU2023311967A1 (en) 2022-07-19 2025-02-06 Pinata Holdings Inc. Inhalable serotonin receptor agonist formulations
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof
EP4584247A2 (en) 2022-09-06 2025-07-16 ATAI Therapeutics, Inc. Heteroatom substituted cyclic and alkyl amines as activators of serotonin receptors
EP4608395A2 (en) 2022-10-26 2025-09-03 ATAI Therapeutics, Inc. N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof
WO2024105379A1 (en) 2022-11-14 2024-05-23 Beckley Psytech Limited Formulations of 5-meo-dmt
WO2024108195A1 (en) 2022-11-17 2024-05-23 Remedi, Inc. Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use
WO2024118767A2 (en) 2022-11-29 2024-06-06 Caamtech, Inc. Tryptamine derivatives
TW202430149A (zh) 2022-12-01 2024-08-01 美商雅特益醫療公司 N,n-二甲基色胺之結晶形式及其使用方法
EP4633625A2 (en) 2022-12-15 2025-10-22 ATAI Therapeutics, Inc. Prodrugs of dimethyltryptamine and derivatives thereof
JP2026501759A (ja) 2023-01-04 2026-01-16 ジーエイチ・リサーチ・アイルランド・リミテッド 薬物パッド
CN120813348A (zh) 2023-01-30 2025-10-17 Gh研究爱尔兰有限公司 用于治疗产后抑郁的5-甲氧基-n,n-二甲基色胺
JP2026505778A (ja) 2023-01-30 2026-02-18 ジーエイチ・リサーチ・アイルランド・リミテッド 産後うつ病の処置における5-meo-dmtの使用
IL322810A (en) 2023-02-17 2025-10-01 Native Code Bio Llc Therapeutic combinations for inflammatory conditions and diseases
EP4704833A2 (en) 2023-04-27 2026-03-11 ATAI Therapeutics, Inc. Alkoxy and carbamoyl quaternary amine salts as prodrugs of trpytamines
GB202306256D0 (en) 2023-04-27 2023-06-14 Beckley Psytech Ltd 5-Methoxy-N,N-Dimethyltryptamine Formulations
JP2026518190A (ja) 2023-05-24 2026-06-04 サイレラ インコーポレイテッド トリプタミン誘導体を含む製剤およびそれらの使用
GB202308830D0 (en) 2023-06-13 2023-07-26 Beckley Psytech Ltd 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) formulations
US20250193970A1 (en) 2023-06-13 2025-06-12 Beckley Psytech Limited 5-METHOXY-N,N-DIMETHYLTRYPTAMINE (5-MeO-DMT) FORMULATIONS
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
WO2024256821A1 (en) 2023-06-13 2024-12-19 Beckley Psytech Limited Pharmaceutical compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt)
EP4746873A1 (en) 2023-07-19 2026-05-27 ATAI Therapeutics, Inc. Novel prodrugs and conjugates of dimethyltryptamine and methods of using the same
EP4750467A1 (en) 2023-07-25 2026-06-03 ATAI Therapeutics, Inc. Compositions for limiting sympathomimetic effects of psychedelic therapeutics
EP4773958A1 (en) 2023-09-08 2026-07-15 ATAI Therapeutics, Inc. Parenteral formulations for n,n-dimethyltryptamine (dmt) and dmt analogs, methods of making, and methods of use thereof
EP4784121A1 (en) 2023-09-28 2026-08-05 Beckley Psytech Limited Pharmaceutical compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt)
EP4788322A1 (en) 2023-10-02 2026-08-12 ATAI Therapeutics, Inc. N-n-dimethyltryptamine (dmt) and dmt analog oral transmucosal film compositions, methods of making, and methods of use thereof
TW202547567A (zh) 2023-10-18 2025-12-16 愛爾蘭商Gh研究愛爾蘭有限公司 用於氣溶膠化藥物給藥之設備、系統及方法
WO2025137581A1 (en) 2023-12-21 2025-06-26 Atai Therapeutics, Inc. Novel tetrahydro pyridine substituted indole and azaindoles, compositions of matter and pharmaceutical compositions
WO2025170990A1 (en) 2024-02-06 2025-08-14 Atai Therapeutics, Inc. Controlled transmucosal release of dmt in combination with a monoamine oxidase inhibitor
WO2026030301A1 (en) 2024-07-29 2026-02-05 Atai Therapeutics, Inc. Methods of treating treatment resistant depression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180021326A1 (en) * 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
US20180221396A1 (en) * 2017-02-09 2018-08-09 CaaMTech, LLC Compositions and methods comprising a psilocybin derivative

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY [online], 2 August 2017 (2017-08-02), ANONYMOUS, retrieved from STN Database on 25 February 2026 *
Nichols, David E.. 'Improvements to the Synthesis of Psilocybin and a Facile Method for Preparing the O-Acetyl Prodrug of Psilocin.' Synthesis 1999 (1999): 935 - 938. *

Also Published As

Publication number Publication date
JP2025089393A (ja) 2025-06-12
CA3182156A1 (en) 2021-11-11
US20250041273A1 (en) 2025-02-06
US20260115167A1 (en) 2026-04-30
US12642787B2 (en) 2026-06-02
US12472163B2 (en) 2025-11-18
IL297861A (en) 2023-01-01
US12053453B2 (en) 2024-08-06
US12396982B2 (en) 2025-08-26
AU2021268204A1 (en) 2022-12-08
US12691098B2 (en) 2026-07-28
US11759452B2 (en) 2023-09-19
US20220354824A1 (en) 2022-11-10
US20210346347A1 (en) 2021-11-11
US20250235428A1 (en) 2025-07-24
US20260115168A1 (en) 2026-04-30
US12685722B2 (en) 2026-07-21
US20260124174A1 (en) 2026-05-07
EP4146198A4 (en) 2024-05-15
JP2023524598A (ja) 2023-06-12
US20230372295A1 (en) 2023-11-23
WO2021226416A1 (en) 2021-11-11
JP7655943B2 (ja) 2025-04-02
JP2025098247A (ja) 2025-07-01
JP7801518B2 (ja) 2026-01-16
US20250064783A1 (en) 2025-02-27
EP4146198A1 (en) 2023-03-15
US11478449B1 (en) 2022-10-25